Sodium chloride solution
Sponsors
Sygnis Bioscience GmbH & Co KG, Sangart, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, PD Dr. Bertram Scheller, Universitaire Ziekenhuizen KU Leuven
Conditions
Acute Ischemic StrokeAnemia, Sickle CellAnesthesiaCAM-ICU Diagnosed DeliriumGeneralized Myasthenia GravisHemoglobin SC DiseaseMultiple Sclerosis, Relapsing-RemittingPostoperative Residual Paralysis
Phase 1
Phase 2
AXIS 2: AX200 for the Treatment of Ischemic Stroke
CompletedNCT00927836
Start: 2009-05-31End: 2011-11-30Updated: 2011-12-13
Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis
WithdrawnNCT01925001
Start: 2013-10-31End: 2015-10-31Updated: 2013-10-28
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
CompletedNCT02251041
Start: 2014-09-30End: 2019-08-31Updated: 2024-08-23
Phase 3
Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery
NCT02216266
Start: 2014-04-30End: 2018-12-31Target: 120Updated: 2017-03-10
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
CompletedNCT02746744
Start: 2016-05-31End: 2021-08-31Updated: 2021-10-12
A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis
CompletedNCT02950155
Start: 2016-10-16End: 2022-01-31Updated: 2024-10-26
Unknown Phase
Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis
CompletedNCT01503840
Start: 2011-12-31End: 2012-07-31Updated: 2014-04-22
Effect of Intraoperative Lidocaine Infusion on Intraoperative Isoflurane Requirements
CompletedNCT03386565
Start: 2016-10-02End: 2017-12-15Updated: 2017-12-29